论文部分内容阅读
摘要在视网膜母细胞瘤的综合治疗中,化学减容(chemoreduction)是一项非常有效且不可替代的方法。但这些化疗药物存在潜在的毒副作用且对中晚期视网膜母细胞瘤的疗效不佳,因此如何减少药物副作用、增强疗效、减少耐药性成为近年来视网膜母细胞瘤研究的热点。研究集中于给药方法的变革和新型药物的研制,这包括眼动脉介入给药,纤维蛋白黏合剂缓释给药,药物直流电离子导入等,一些新的治疗药物的应用,如MDM2抑制剂(nutlins)、吩恶嗪衍生物Phx-1、考布他汀A4磷酸盐(combretastatin A4 phosphate,CA4P)、2-脱氧-d-葡萄糖(2-deoxy-d-glucose,2-DG)、组蛋白去乙酰化酶抑制剂(HDACi,包括TSA、HASA、MS-275、BL1521)等。本文将从这两个方面对近几年视网膜母细胞瘤的药物使用和研究进展作一综述。
Abstract In the comprehensive treatment of retinoblastoma, chemoreduction is a very effective and irreplaceable method. However, these chemotherapeutic drugs have potential side effects and are not effective in the treatment of advanced retinoblastoma. Therefore, how to reduce drug side effects, enhance efficacy and reduce drug resistance has become a hot research topic in recent years. The research focuses on the change of drug delivery methods and the development of new drugs. These include the intervention of ophthalmic artery, the sustained release of fibrin adhesive and the introduction of drug DC ion. Some new therapeutic drugs such as MDM2 inhibitor nutlins, phenoxazine derivatives Phx-1, combretastatin A4 phosphate (CA4P), 2-deoxy-d-glucose Acetylating enzyme inhibitors (HDACi, including TSA, HASA, MS-275, BL1521) and the like. This article will review the use and research progress of retinoblastoma in these two aspects in recent years.